PsyKey Inc Completes Definitive Agreement with MycoVita to establish a Strategic Partnership focused on Research, Development and Commercialization of Mycology based Products
CeCors, Inc. (OTC PINK:CEOS) announces a strategic partnership with MycoVita Canada Inc. through its subsidiary, PsyKey Inc.. This alliance aims to enhance growth and market presence in the mycology sector by focusing on the research, development, and commercialization of mycology-based products and therapeutics. The partnership grants exclusive access to MycoVita’s formulations and research, potentially unlocking new distribution channels and revenue streams. Dr. Omon Isikhuemhen, an expert in mushroom science, leads this collaboration, promising advancements in product quality and efficacy.
- Strategic partnership with MycoVita expected to enhance market share and growth.
- Exclusive access to MycoVita's formulations and research.
- Potential to open new distribution channels.
- Collaboration with Dr. Omon Isikhuemhen, an expert in mushroom science.
- Risks of not achieving projected sales or revenue growth.
- Potential litigation costs that could affect operations.
- Forward-looking statements may not guarantee future performance.
CARSON CITY, NV / ACCESSWIRE / May 11, 2021 / CECORS, INC. (OTC PINK:CEOS) ("CeCors" or the "Company"), through its wholly-owned subsidiary PsyKey Inc. is pleased to announce it has entered into a definitive agreement to form an exclusive strategic partnership with MycoVita Canada Inc., that is expected to accelerate the growth and market share for both companies, in the fast-growing mycology-based markets. The Partnership will be executed via a wholly-owned subsidiary of PsyKey Inc. with the purpose of the Partnership being the Research, development, and commercialization of Mycology based formulations, products, and therapeutics, as well as the development of innovative sustainable food production strategies.
MycoVita is a Biotech company focused on the development of functional foods and products, that support optimal health and wellbeing through science-backed formulations and research. MycoVita holds numerous formulations that are composed of natural occurring compounds sourced only from the highest quality raw ingredients, under the supervision and guidance of its world-class team.
The MycoVita team includes Dr. Omon Isikhuemhen who is an internationally recognized researcher and professor in the field of mushroom science and fungal biotechnology. Dr. Isikhuemhen's credentials include a Bachelor of Science with honors, a Master's of Science in Botany, as well as a Doctor of Philosophy in Microbiology. Dr. Isikhuemhen is a trailblazer in research and development that has resulted in numerous scientific publications and technological advancements.
This strategic partnership will provide PsyKey Inc. exclusive access to formulations, science-backed research, supply chain security, and new potential distribution channels.
"Partnering with MycoVita will not only provide PsyKey the opportunity to offer consumers unmatched quality and efficacy in its product offerings, but it will also open doors in the mushroom industry and mycology world by working alongside Dr. Isikhuemhen. This will allow us to further gain and develop opportunity to provide long-term growth and new revenue streams for the company," said Amar Bhatal, president of CeCors Inc.
For further information:
Publicly traded company (OTC PINK:CEOS)
Website: www.psykeyworld.com
E-mail: info@psykeyworld.com
Follow us on Twitter: https://twitter.com/PsyKeyworld
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements.
SOURCE: CeCors, Inc.
View source version on accesswire.com:
https://www.accesswire.com/646220/PsyKey-Inc-Completes-Definitive-Agreement-with-MycoVita-to-establish-a-Strategic-Partnership-focused-on-Research-Development-and-Commercialization-of-Mycology-based-Products
FAQ
What is the significance of the partnership between CeCors and MycoVita?
How will the partnership affect CeCors's future business operations?
Who is Dr. Omon Isikhuemhen and what role does he play in the partnership?
What are the risks associated with the new partnership for CeCors?
What is the stock symbol for CeCors?
